What is the best management to prevent excessive maternal bleeding during labor for a pregnant woman with von Willebrand disease?

Management of Von Willebrand Disease During Labor

For a pregnant woman with von Willebrand disease in labor, measure von Willebrand factor (VWF) and factor VIII levels immediately and administer prophylactic treatment if levels are below 50 IU/dL to prevent postpartum hemorrhage.

Pre-Delivery Assessment and Risk Stratification

• Check VWF activity (ristocetin cofactor) and factor VIII levels at 34-36 weeks gestation and again upon admission to labor and delivery 1, 2, 3
• Women with baseline VWF and factor VIII levels >30 IU/dL typically normalize these levels by the third trimester and may not require prophylaxis 1
• Women with levels <50 IU/dL at term require prophylactic hemostatic treatment before delivery or any invasive procedure 2, 3
• Those with baseline levels <20 IU/dL usually show inadequate physiologic rise during pregnancy and will need replacement therapy 1

Treatment Selection Based on VWD Type

Type 1 VWD (Mild Quantitative Deficiency)

• Desmopressin (DDAVP) 0.3 mcg/kg IV is the preferred first-line treatment when VWF/factor VIII levels remain <50 IU/dL at delivery 4, 3
• Administer 30 minutes prior to scheduled delivery or at onset of active labor 4
• DDAVP is effective in most type 1 patients and some type 2A patients 3
• Verify prior response to DDAVP during pregnancy or preconception testing, as some patients with increased VWF clearance may not respond adequately 1

Type 2 VWD (Qualitative Deficiency)

• Type 2A and 2M: DDAVP may be used if prior testing confirms adequate response; otherwise use VWF/factor VIII concentrate 3
• Type 2B: DDAVP is contraindicated due to risk of thrombocytopenia; use VWF/factor VIII concentrate exclusively 1, 3
• Type 2N: Requires VWF/factor VIII concentrate as DDAVP is ineffective 3

Type 3 VWD (Severe Deficiency)

• VWF/factor VIII concentrate is mandatory; DDAVP is ineffective 1, 3
• Target VWF activity and factor VIII levels >50 IU/dL for vaginal delivery, >100 IU/dL for cesarean section 5, 2

Delivery Planning and Anesthesia Considerations

Mode of Delivery

• Vaginal delivery is preferred when obstetric conditions permit 6
• Avoid fetal scalp electrodes, fetal scalp sampling, and vacuum/rotational forceps delivery to minimize fetal bleeding risk 6
• Cesarean section requires higher target factor levels (>100 IU/dL) due to surgical bleeding risk 2

Neuraxial Anesthesia

• Epidural or spinal anesthesia can be safely administered only when VWF activity and factor VIII levels are ≥50 IU/dL 6, 2
• Verify levels within 12-24 hours before planned neuraxial placement 2
• If levels are inadequate, treat with DDAVP or concentrate first, then recheck levels before proceeding 3

Intrapartum and Immediate Postpartum Management

Active Bleeding During Delivery

• First-line: Administer DDAVP (if appropriate for VWD type) plus tranexamic acid 1g IV every 6-8 hours 6, 5
• Second-line: VWF/factor VIII concentrate if DDAVP contraindicated, ineffective, or type 2B/3 VWD 5, 1
• Tranexamic acid is particularly useful for mucosal bleeding and should be continued for 7-14 days postpartum to control lochia 1, 2

Postpartum Hemorrhage Protocol

• If first-line hemostatic treatment fails, escalate to VWF/factor VIII concentrate immediately 5
• Target VWF activity and factor VIII levels >50 IU/dL until bleeding controlled 2
• Standard obstetric measures (uterotonic agents, uterine massage, surgical interventions) should proceed concurrently 6

Extended Postpartum Prophylaxis

• Continue prophylactic treatment for at least 3-5 days postpartum, extending to 2 weeks in high-risk cases 7, 2, 3
• Delayed postpartum hemorrhage occurs in up to 20% of women with VWD, typically 7-14 days after delivery when VWF/factor VIII levels decline 1, 2
• Recheck VWF and factor VIII levels at 3-5 days postpartum; if <50 IU/dL, continue prophylaxis 2
• Tranexamic acid 1g orally three times daily for 10-14 days is recommended at discharge to prevent excessive lochia 1, 2
• Close follow-up for at least 6 weeks postpartum with hematology consultation 7

Critical Pitfalls to Avoid

• Do not assume pregnancy has normalized VWF levels without laboratory confirmation at term 1
• Do not use DDAVP in type 2B VWD due to risk of severe thrombocytopenia and paradoxical bleeding 1, 3
• Do not discontinue prophylaxis immediately after delivery; delayed hemorrhage risk persists for 2 weeks 2, 3
• Do not perform neuraxial anesthesia without documented VWF activity and factor VIII ≥50 IU/dL 6, 2
• Avoid aspirin and NSAIDs throughout pregnancy and postpartum period due to platelet dysfunction 1